With broadened use of newer prostate-specific membrane antigen (PSMA)–based radioligands to identify the location of prostate cancer using PET, the treatment of BCR is rapidly changing to more personalized and targeted approaches (4). This evidence concerns the gene BCR and Familial prostate cancer.